SKF-80723

SKF-80723 is a **small molecule drug** classified as a benzazepine derivative and acts as a **dopamine D1 receptor agonist**[1][7][3][5]. It is structurally characterized as a 6-bromo analogue within the benzazepine class and has demonstrated high selectivity and affinity for the dopamine D1 receptor in preclinical models[5][3]. SKF-80723 was initially developed by Smithkline Beecham Pharmaceuticals (India) Ltd.[1]. Experimental studies primarily investigated its use for **neurological disorders**, notably **Parkinson's disease**, aiming to improve motor symptoms through D1 receptor stimulation [1][3][5]. It has shown efficacy in stimulating adenylate cyclase activity in striatal tissue and produced behavioral effects such as contralateral circling and increased locomotion in lesioned animal models[3][5]. However, there is no evidence of clinical development beyond early-stage research, and no record of human clinical trials or regulatory approval has been identified[1][9].

Other names

SKF-80723 HBrSKF80723 HBrSKF 80723 HBr